These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2004-001103-35||Exemestane in Advanced or Recurrent Endometrial Carcinoma. A multicentre non-randomized Phase II study||not-yet-due|
|Exempt||2004-001356-37||Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer||not-yet-due|
|Ongoing||2004-002429-37||A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2.||not-yet-due|
|Ongoing||2004-005218-35||A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma||not-yet-due|
|Ongoing||2014-004269-26||Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal ca...||not-yet-due|
|Ongoing||2016-000193-38||ENGOT-EN1/FANDANGO: A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer.||not-yet-due|
|Listed as ongoing, but also has a completion date||2016-001848-20||A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive ad...||2021-12-01||bad-data|
|Ongoing||2017-002805-36||NSGO-OV-UMB1; ENGOT OV30: A phase II umbrella trial in patients with relapsed ovarian cancer. Vaiheen II usean hoitohaaran tutkimus uusiutunutta munasarjasyöpää sairastavilla potilailla.||not-yet-due|
|Reported results Terminated||2018-003756-20||A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer||2019-10-10||due-trials|
|Ongoing||2020-004738-39||ENGOT-OV56-NSGO-CTU-DOVACC. A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.||not-yet-due|